Payment overview · 2025
General Payments
$646.64
37 reported records · 15 companies
Healthcare provider profile · identity verified
Alan J Spanel, MD
Allopathic & Osteopathic Physicians|Internal Medicine · NORFOLK, NE · NPI 1023508892
Verified facts
What the public records show
CMS Open Payments records show Alan J Spanel, MD received $646.64 in general payments during 2025 across 37 reported records.
ABBVIE INC. accounted for 21.6% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 20 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Jardiance, Ozempic, Rybelsus, Zenpep.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 19 claims for Synthroid by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported VRAYLAR as an associated drug or biological on 377741 records involving 62704 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Vraylar by this doctor in 2024.
Aimmune Therapeutics, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ZENPEP as an associated drug or biological on 32144 records involving 12432 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Zenpep by this doctor in 2024.
Astellas Pharma US Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Myrbetriq as an associated drug or biological on 16 records involving 16 distinct recipient NPIs. Public Medicare Part D data also shows 61 claims for Myrbetriq by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 31 claims for Farxiga by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 182 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 59 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 51 claims for Trulicity by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 62 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Rybelsus as an associated drug or biological on 161257 records involving 55409 distinct recipient NPIs. Public Medicare Part D data also shows 17 claims for Rybelsus by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 134 claims for Eliquis by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PAXLOVID as an associated drug or biological on 24465 records involving 15715 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Paxlovid by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| ABBVIE INC. | Unresolved — no canonical attribution shown | $139.60 | 21.6% | 7 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $119.75 | 18.5% | 8 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $73.39 | 11.3% | 4 | 2025 |
| SANOFI-AVENTIS U.S. LLC | Unresolved — no canonical attribution shown | $60.11 | 9.3% | 1 | 2025 |
| Lundbeck LLC | Unresolved — no canonical attribution shown | $40.46 | 6.3% | 2 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $35.57 | 5.5% | 2 | 2025 |
| Phathom Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $35.31 | 5.5% | 5 | 2025 |
| Abbott Laboratories | Unresolved — no canonical attribution shown | $23.75 | 3.7% | 1 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $21.04 | 3.2% | 1 | 2025 |
| Mallinckrodt Hospital Products Inc. | Unresolved — no canonical attribution shown | $18.86 | 2.9% | 1 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $17.40 | 2.7% | 1 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $16.20 | 2.5% | 1 | 2025 |
| Xeris Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $15.53 | 2.4% | 1 | 2025 |
| Astellas Pharma US Inc | Unresolved — no canonical attribution shown | $15.22 | 2.4% | 1 | 2025 |
| Aimmune Therapeutics, Inc. | Unresolved — no canonical attribution shown | $14.45 | 2.2% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $646.64 | 37 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $111.02 | 6 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $87.10 | 5 | 2025 |
Source payment records
|
|||||
| TZIELD Normalized: tzield |
Biological | SANOFI-AVENTIS U.S. LLC | $60.11 | 1 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Lundbeck LLC, Otsuka America Pharmaceutical, Inc. | $56.66 | 3 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $54.73 | 3 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $42.58 | 3 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $35.57 | 2 | 2025 |
Source payment records
|
|||||
| ZAVZPRET Normalized: zavzpret |
Drug | PFIZER INC. | $35.57 | 2 | 2025 |
Source payment records
|
|||||
| VOQUEZNA Normalized: voquezna |
Drug | Phathom Pharmaceuticals, Inc. | $35.31 | 5 | 2025 |
Source payment records
|
|||||
| BOTOX Normalized: botox |
Biological | ABBVIE INC. | $28.58 | 1 | 2025 |
Source payment records
|
|||||
| FREESTYLE LIBRE 3 Normalized: freestyle libre 3 |
Device | Abbott Laboratories | $23.75 | 1 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Lilly USA, LLC | $21.04 | 1 | 2025 |
Source payment records
|
|||||
| ACTHAR Normalized: acthar |
Biological | Mallinckrodt Hospital Products Inc. | $18.86 | 1 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $18.66 | 1 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $18.66 | 1 | 2025 |
Source payment records
|
|||||
| EVENITY Normalized: evenity |
Biological | Amgen Inc. | $17.40 | 1 | 2025 |
Source payment records
|
|||||
| PROLIA Normalized: prolia |
Biological | Amgen Inc. | $17.40 | 1 | 2025 |
Source payment records
|
|||||
| GVOKE HYPOPEN Normalized: gvoke hypopen |
Drug | Xeris Pharmaceuticals, Inc. | $15.53 | 1 | 2025 |
Source payment records
|
|||||
| Veozah Normalized: veozah |
Drug | Astellas Pharma US Inc | $15.22 | 1 | 2025 |
Source payment records
|
|||||
| ZENPEP Normalized: zenpep |
Drug | Aimmune Therapeutics, Inc. | $14.45 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 182 | exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 62 | exact normalized | Medicare Part D |
| Rybelsus rybelsus |
2025 | Rybelsus | 2024 | 17 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| ZENPEP zenpep |
2025 | Zenpep | 2024 | 12 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
19 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | VRAYLAR open payments reported associated product |
CMS Open Payments — General Payments 377741 supporting records · 62704 recipient NPIs · example record 1201352550 |
Vraylar · 2024 Exact normalized brand match · 1 Part D row |
11 | suppressed by CMS |
| Aimmune Therapeutics, Inc. Exact reporting entity; no affiliate inference |
2025 | ZENPEP open payments reported associated product |
CMS Open Payments — General Payments 32144 supporting records · 12432 recipient NPIs · example record 1249641927 |
Zenpep · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
| Astellas Pharma US Inc Exact reporting entity; no affiliate inference |
2025 | Myrbetriq open payments reported associated product |
CMS Open Payments — General Payments 16 supporting records · 16 recipient NPIs · example record 1238599014 |
Myrbetriq · 2024 Exact normalized brand match · 1 Part D row |
61 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
31 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
182 | 25 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
59 | 12 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
51 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
62 | 12 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Rybelsus open payments reported associated product |
CMS Open Payments — General Payments 161257 supporting records · 55409 recipient NPIs · example record 1188130076 |
Rybelsus · 2024 Exact normalized brand match · 1 Part D row |
17 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
134 | 32 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | PAXLOVID open payments reported associated product |
CMS Open Payments — General Payments 24465 supporting records · 15715 recipient NPIs · example record 1228794432 |
Paxlovid · 2024 Exact normalized brand match · 1 Part D row |
13 | 13 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Levothyroxine Sodium | Levothyroxine Sodium | 453 | 81 |
| Atorvastatin Calcium | Atorvastatin Calcium | 369 | 85 |
| Losartan Potassium | Losartan Potassium | 301 | 75 |
| Pantoprazole Sodium | Pantoprazole Sodium | 289 | 62 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 239 | 52 |
| Amlodipine Besylate | Amlodipine Besylate | 231 | 60 |
| Gabapentin | Gabapentin | 195 | 45 |
| Jardiance | Empagliflozin | 182 | 25 |
| Furosemide | Furosemide | 146 | 33 |
| Sertraline Hcl | Sertraline Hcl | 136 | 32 |
| Potassium Chloride | Potassium Chloride | 135 | 36 |
| Eliquis | Apixaban | 134 | 32 |
| Omeprazole | Omeprazole | 124 | 32 |
| Mirtazapine | Mirtazapine | 120 | 24 |
| Lisinopril | Lisinopril | 117 | 34 |
| Escitalopram Oxalate | Escitalopram Oxalate | 113 | 26 |
| Metformin Hcl | Metformin Hcl | 105 | 24 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 99 | 17 |
| Montelukast Sodium | Montelukast Sodium | 97 | 20 |
| Famotidine | Famotidine | 92 | 16 |
| Allopurinol | Allopurinol | 87 | 13 |
| Metoprolol Tartrate | Metoprolol Tartrate | 87 | 21 |
| Simvastatin | Simvastatin | 83 | 15 |
| Trazodone Hcl | Trazodone Hcl | 82 | 15 |
| Donepezil Hcl | Donepezil Hcl | 81 | 16 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 81 | 19 |
| Alprazolam | Alprazolam | 78 | 17 |
| Memantine Hcl | Memantine Hcl | 77 | 16 |
| Pravastatin Sodium | Pravastatin Sodium | 77 | 20 |
| Carvedilol | Carvedilol | 76 | 18 |
| Tramadol Hcl | Tramadol Hcl | 73 | 27 |
| Duloxetine Hcl | Duloxetine Hcl | 70 | 18 |
| Hydrochlorothiazide | Hydrochlorothiazide | 68 | 19 |
| Fluticasone Propionate | Fluticasone Propionate | 64 | 30 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 62 | 14 |
| Metoprolol Succinate | Metoprolol Succinate | 62 | 24 |
| Ozempic | Semaglutide | 62 | 12 |
| Myrbetriq | Mirabegron | 61 | suppressed |
| Mounjaro | Tirzepatide | 59 | 12 |
| Buspirone Hcl | Buspirone Hcl | 56 | 16 |
| Januvia | Sitagliptin Phosphate | 56 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 55 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 55 | suppressed |
| Trulicity | Dulaglutide | 51 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 50 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 50 | 16 |
| Amitriptyline Hcl | Amitriptyline Hcl | 49 | 13 |
| Tamsulosin Hcl | Tamsulosin Hcl | 48 | 12 |
| Lamotrigine | Lamotrigine | 46 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 44 | 13 |
| Lorazepam | Lorazepam | 44 | 15 |
| Novolog Flexpen | Insulin Aspart | 43 | 11 |
| Bupropion Xl | Bupropion Hcl | 42 | 11 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 41 | 33 |
| Ondansetron Hcl | Ondansetron Hcl | 41 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 40 | suppressed |
| Bumetanide | Bumetanide | 39 | suppressed |
| Meloxicam | Meloxicam | 38 | suppressed |
| Prednisone | Prednisone | 38 | 17 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 36 | 21 |
| Oxycodone Hcl | Oxycodone Hcl | 35 | 16 |
| Bupropion Hcl Sr | Bupropion Hcl | 34 | suppressed |
| Pregabalin | Pregabalin | 34 | suppressed |
| Repatha Sureclick | Evolocumab | 34 | suppressed |
| Aripiprazole | Aripiprazole | 33 | suppressed |
| Atenolol | Atenolol | 33 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 32 | suppressed |
| Spironolactone | Spironolactone | 32 | suppressed |
| Clopidogrel | Clopidogrel Bisulfate | 31 | 11 |
| Farxiga | Dapagliflozin Propanediol | 31 | suppressed |
| Zolpidem Tartrate | Zolpidem Tartrate | 31 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 30 | suppressed |
| Cephalexin | Cephalexin | 29 | 14 |
| Doxazosin Mesylate | Doxazosin Mesylate | 28 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 28 | 11 |
| Vascepa | Icosapent Ethyl | 28 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 27 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 26 | 21 |
| Kerendia | Finerenone | 26 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 26 | 22 |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 25 | suppressed |
| Clonazepam | Clonazepam | 25 | suppressed |
| Fenofibrate | Fenofibrate | 25 | suppressed |
| Ibuprofen | Ibuprofen | 25 | suppressed |
| Midodrine Hcl | Midodrine Hcl | 23 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 23 | 18 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 23 | 18 |
| Ezetimibe | Ezetimibe | 22 | suppressed |
| Glipizide Er | Glipizide | 22 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 22 | suppressed |
| Topiramate | Topiramate | 22 | suppressed |
| Celecoxib | Celecoxib | 21 | suppressed |
| Humalog Kwikpen U-100 | Insulin Lispro | 21 | suppressed |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 20 | 11 |
| Xarelto | Rivaroxaban | 20 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 19 | suppressed |
| Loperamide | Loperamide Hcl | 19 | 12 |
| Synthroid | Levothyroxine Sodium | 19 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 19 | suppressed |
| Tresiba Flextouch U-200 | Insulin Degludec | 19 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 19 | suppressed |
| Risperidone | Risperidone | 18 | suppressed |
| Spiriva Respimat | Tiotropium Bromide | 18 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 17 | suppressed |
| Azithromycin | Azithromycin | 17 | 15 |
| Nystatin | Nystatin | 17 | 11 |
| Rybelsus | Semaglutide | 17 | suppressed |
| Temazepam | Temazepam | 17 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 17 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 16 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 16 | suppressed |
| Fluconazole | Fluconazole | 16 | 11 |
| Ibu | Ibuprofen | 16 | suppressed |
| Icosapent Ethyl | Icosapent Ethyl | 16 | suppressed |
| Mupirocin | Mupirocin | 16 | suppressed |
| Primidone | Primidone | 16 | suppressed |
| Cholestyramine | Cholestyramine (With Sugar) | 15 | suppressed |
| Cholestyramine Light | Cholestyramine | 15 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 15 | suppressed |
| Folic Acid | Folic Acid | 15 | suppressed |
| Levetiracetam | Levetiracetam | 15 | suppressed |
| Ondansetron Odt | Ondansetron | 15 | suppressed |
| Ultra-Fine Nano Pen Needle | Pen Needle, Diabetic | 15 | suppressed |
| Chlorthalidone | Chlorthalidone | 14 | suppressed |
| Divalproex Sodium | Divalproex Sodium | 14 | suppressed |
| Glucagon Emergency Kit | Glucagon | 14 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 14 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 14 | suppressed |
| Trulance | Plecanatide | 14 | suppressed |
| Colestipol Hcl | Colestipol Hcl | 13 | suppressed |
| Latanoprost | Latanoprost | 13 | suppressed |
| Methenamine Hippurate | Methenamine Hippurate | 13 | suppressed |
| Methylphenidate Hcl | Methylphenidate Hcl | 13 | suppressed |
| Nyamyc | Nystatin | 13 | suppressed |
| Paxlovid | Nirmatrelvir/Ritonavir | 13 | 13 |
| Raloxifene Hcl | Raloxifene Hcl | 13 | suppressed |
| Trospium Chloride | Trospium Chloride | 13 | suppressed |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 12 | suppressed |
| Amoxicillin | Amoxicillin | 12 | suppressed |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 12 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 12 | suppressed |
| Doxepin Hcl | Doxepin Hcl | 12 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 12 | suppressed |
| Metolazone | Metolazone | 12 | suppressed |
| Quviviq | Daridorexant Hcl | 12 | suppressed |
| Zenpep | Lipase/Protease/Amylase | 12 | suppressed |
| Gemfibrozil | Gemfibrozil | 11 | suppressed |
| Insulin Aspart Flexpen | Insulin Aspart | 11 | suppressed |
| Irbesartan | Irbesartan | 11 | suppressed |
| Propylthiouracil | Propylthiouracil | 11 | suppressed |
| Sevelamer Carbonate | Sevelamer Carbonate | 11 | suppressed |
| Vraylar | Cariprazine Hcl | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $646.64 · 37 records | ABBVIE INC. | ACTHAR, AIRSUPRA, BOTOX, EVENITY, FREESTYLE LIBRE 3, GVOKE HYPOPEN, JARDIANCE, NURTEC ODT, Ozempic, PROLIA, QULIPTA, REXULTI, Rybelsus, TZIELD, UBRELVY, VOQUEZNA, Veozah, Wegovy, ZAVZPRET, ZENPEP | 12 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Jardiance play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error